ARCHIMED Invests in PlasmidFactory
October 7, 2022
Transatlantic healthcare private equity firm ARCHIMED (via its MED Platform II fund) has invested in PlasmidFactory, a Bielefeld, Germany-based contract manufacturer of plasmid and minicircle DNA used in gene and cell therapies. The founder and management will remain in place with a roll-over of a portion of proceeds; proceeds will fund rapid expansion including construction of a larger GMP-compliant production facility to meet growing demand.
- Targets
- PlasmidFactory
- Industry
- Biotechnology
- Location
- North Rhine-Westphalia, Germany
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
ARCHIMED Acquires Majority Stake in ExcellGene and Magellan Biologics
September 25, 2025
Biotechnology
ARCHIMED, a healthcare-focused private equity firm, has acquired a majority stake in Switzerland-based ExcellGene SA and its sister company Magellan Biologics & Consulting (Portugal), partnering with founders Florian and Maria Wurm and management. The investment creates a group focused on cell line development, gene transfer and cell culture-based manufacturing to accelerate work on biosimilars, recombinant proteins and transfection/media products.
-
ARCHIMED Acquires Majority Stake in Title21 Health Solutions
July 12, 2022
Healthcare Services
ARCHIMED has acquired a majority stake in Phoenix-based Title21 Health Solutions through its MED III fund, with founders Lynn Fischer and Kent Kirimli retaining a significant minority. Title21 is an end-to-end software provider for cell and gene therapy labs; ARCHIMED plans to accelerate R&D, international expansion (Europe and Asia) and further digitization of the sector.
-
ARCHIMED Acquires Majority Stake in Cube (Cube Biotech)
November 3, 2021
Biotechnology
Transatlantic healthcare private equity firm ARCHIMED has purchased a majority stake in Monheim, Germany-based Cube (Cube Biotech), a specialist provider of high-purity, stable membrane proteins for drug discovery. ARCHIMED will support Cube's US market expansion and broaden its product and service offering organically and via acquisitions while Cube's founding management remain significant shareholders and continue to lead the business.
-
ARCHIMED Acquires Majority Stake in Xpress Biologics
October 5, 2021
Biotechnology
ARCHIMED has acquired a majority stake in Liège-based Xpress Biologics and will finance a ten-fold expansion of the company's plasmid DNA production capacity with the implementation of GMP services. Founders Christian Rodriguez, Philippe Ledent and Marc Daukandt, together with public investor Noshaq, will reinvest proceeds; ARCHIMED is investing via its MED II fund to help internationalize distribution into the US and Asia‑Pacific.
-
ARCHIMED Acquires Majority Stake in Germany's Zyto Group
January 12, 2021
Medical Devices
ARCHIMED, through its MED II fund, has acquired a majority stake in the Zyto group — a German developer, manufacturer and distributor of advanced cancer diagnostics, including Zytomed, ZytoVision and 42 Life Sciences. The deal will keep founders and management as significant minority shareholders and is intended to accelerate product innovation, regulatory capabilities and international expansion of the group's precision oncology diagnostics.
-
Warburg Pincus and ArchiMed Invest in Polyplus-transfection
April 29, 2020
Biotechnology
Warburg Pincus has made a major growth investment in Polyplus-transfection SA alongside existing majority shareholder ArchiMed, with both firms becoming equal shareholders while Polyplus management remains significant minority owners. The capital will be used to expand production capacity, accelerate product innovation, increase international expansion, and hire across technical, regulatory, and commercial functions to serve the gene and cell therapy market.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.